Want to see JP:7702 full AI Analyst Report?
7702 Stock Chart & Stats
¥442.00
-¥3.00(-0.69%)
At close: 4:00 PM EST
¥442.00
-¥3.00(-0.69%)
Day’s Range― - ―
52-Week Range¥418.00 - ¥478.00
Previous CloseN/A
Volume24.60K
Average Volume (3M)25.73K
Market Cap
¥11.07B
Enterprise Value¥30.77K
Total Cash (Recent Filing)¥8.78B
Total Debt (Recent Filing)¥26.15B
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.75%
Share Statistics
EPS (TTM)-28.66
Shares Outstanding24,733,465
10 Day Avg. Volume27,210
30 Day Avg. Volume25,726
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.16
P/FCF Ratio-11.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stable Balance SheetThe equity cushion and moderate debt load provide financial resilience and support ongoing operations. Although leverage has risen, the balance sheet remains sufficiently stable to absorb near-term earnings weakness.
Positive Operating Cash FlowConsistently positive operating cash flow indicates that the core business continues to convert activity into cash despite weak earnings. This supports working-capital needs and reduces, though does not eliminate, dependence on external financing.
Broad Medical Device PortfolioExposure across multiple hospital and clinical applications broadens the company’s addressable demand base. This product breadth can reduce dependence on one procedure category and provide a durable platform for serving recurring medical-supply needs.
Bears Say
Revenue ContractionDeclining revenue signals weaker demand, volume, pricing, or market execution and limits operating leverage. If this trend persists, it can make fixed costs harder to absorb and further pressure margins and profitability.
Profitability DeteriorationThe return to a net loss after prior profits demonstrates that earnings remain structurally fragile. Thin operating profit leaves little buffer against cost inflation, weaker volumes, or product-mix pressure, limiting internally funded growth.
Weak Free Cash FlowRepeatedly negative free cash flow reduces the company’s ability to fund investment, repay debt, or sustain distributions from internally generated resources. Continued weakness could increase reliance on financing or existing balance-sheet liquidity.
JMS Co., Ltd. News
7702 FAQ
What was JMS Co., Ltd.’s price range in the past 12 months?
JMS Co., Ltd. lowest stock price was ¥418.00 and its highest was ¥478.00 in the past 12 months.
What is JMS Co., Ltd.’s market cap?
JMS Co., Ltd.’s market cap is ¥11.07B.
When is JMS Co., Ltd.’s upcoming earnings report date?
JMS Co., Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 54 days.
How were JMS Co., Ltd.’s earnings last quarter?
JMS Co., Ltd. released its earnings results on Aug 07, 2026. The company reported -¥15.48 earnings per share for the quarter.
Is JMS Co., Ltd. overvalued?
According to Wall Street analysts JMS Co., Ltd.’s price is currently Overvalued.
Does JMS Co., Ltd. pay dividends?
JMS Co., Ltd. pays a Semiannually dividend of ¥8.5 which represents an annual dividend yield of 3.75%. See more information on JMS Co., Ltd. dividends here
What is JMS Co., Ltd.’s EPS estimate?
JMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JMS Co., Ltd. have?
JMS Co., Ltd. has 24,733,465 shares outstanding.
What happened to JMS Co., Ltd.’s price movement after its last earnings report?
JMS Co., Ltd. reported an EPS of -¥15.48 in its last earnings report. Following the earnings report the stock price went up 1.126%.
Which hedge fund is a major shareholder of JMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7702
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JMS Co., Ltd.
JMS Co., Ltd., established in 1947 and headquartered in Hiroshima, Japan, specializes in the development, manufacture, distribution, and global trade of a wide array of medical devices and pharmaceuticals. Its extensive product catalog serves both Japanese and international markets, addressing diverse medical needs. The company provides a comprehensive range of items for infusion and transfusion therapy, including infusion/transfusion sets (some featuring needle-free access ports), single-use needles and syringes, secure scalp vein sets, safe intravenous catheters, extension tubing, oral and enteral feeding systems, infusion and syringe delivery pumps, devices for administering semi-solid nutritional supplements, as well as blood bags, blood collection scales and mixers, high-frequency tube sealing equipment, and serum collection apparatus. For general medical use, JMS offers essential consumables for healthcare institutions such as surgical and examination gloves (both latex and plastic), treatment drapes, surgical gowns, protective masks and caps, drainage receptacles, and surgical adhesive tapes. Furthermore, JMS is a key supplier for hemodialysis and peritoneal dialysis, providing centralized dialysate delivery systems, hemodialysis units, AV fistula needles, systems designed to prevent accidental needlestick injuries, blood tubing sets for hemodialysis, dialyzers, pre-filled syringes, complete hemodialysis kits, single-patient dialysis devices, dialysis solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD), and automated peritoneal dialysis equipment. The company also offers specialized products for cardiovascular therapy, which encompass cardiopulmonary support systems, membrane oxygenators, heat exchange units, pacemakers, microcatheters, and blood tubing sets for cardiopulmonary bypass.




